Kelsey Goodwin Initiated (URGN) at Strong Buy and Held Target at $40 on, Aug 22nd, 2024
Kelsey Goodwin of Guggenheim, Initiated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $40 on, Aug 22nd, 2024.
Kelsey has made no other calls on URGN in the last 4 months.
There are 3 other peers that have a rating on URGN. Out of the 3 peers that are also analyzing URGN, 0 agree with Kelsey's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Kelsey
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $60 on, Thursday, August 15th, 2024
- Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $40 on, Friday, June 14th, 2024
- Matthew Kaplan of "Ladenburg Thalmann" Maintained at Strong Buy with Increased Target to $54 on, Friday, June 14th, 2024
Contributing Sources